Apogee (AACP) news
Recent news
Apogee Therapeutics Inc: Wedbush cuts to neutral from outperform
Wedbush Securities has revised its stance on Apogee Therapeutics Inc. (NASDAQ:APGE), downgrading the stock from "Outperform" to "Neutral". This adjustment follows recent developments in the company’s clinical pipeline and evolving market dynamics. Previously, Wedbush had raised its price target for…
AInvest Wire · Jun 22, 2026ImportantApogee shares jump by record 47% after M&A deal; AbbVie up 3.3%
AInvest Wire · Jun 22, 2026AbbVie exec says company will fund Apogee deal with debt - conf call
AInvest Wire · Jun 22, 2026Moody's Ratings says that AbbVie's acquisition of Apogee adds promising eczema candidate with clinical execution risk
Moody’s Ratings has issued an analysis of AbbVie’s recent acquisition of Apogee Biopharma, highlighting both opportunities and risks associated with the deal. The acquisition brings a promising eczema candidate into AbbVie’s portfolio, which could strengthen its dermatology offerings. However,…
AInvest Wire · Jun 22, 2026Apogee Therapeutics - enters IL-31R license agreement with Paragon on June 17, 2026 - SEC filing
Apogee Therapeutics Inc. (NASDAQ: APOG) has entered into a licensing agreement with Paragon Biopharma for the development and commercialization of a therapeutic targeting the IL-31R pathway, according to a recent SEC filing [引用越界:1]. The agreement, announced on June 17, 2026, grants Paragon…
AInvest Wire · Jun 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.